INDUSTRY

Dr. Yuying Gao will lecture on the value of modeling and simulation for regulatory submission at University of Tokyo's Graduate School of Pharmaceutical Sciences -- Pharsight Corporation announced that Yuying Gao, M.D., Ph.D., Senior Scientist, will speak to members of the Japanese pharmaceutical industry attending the 28th mini-symposium of the Department of Molecular Pharmacokinetics, to be held at the University of Tokyo on March 23, 2006. Dr. Gao will give a presentation on the strategic value of quantitative modeling and simulation to support regulatory submission, along with panelists from industry and academia, as part of a university-sponsored symposium entitled, "The Role of PK/PD Simulation in Drug Development: Is it Possible to Link the Simulation to the Regulatory Science?" The session will include applications of modeling and simulation to support key decisions, and will describe research on how "in silico" methods and technology have been used to predict pharmacokinetics in humans, treatment strategies, and drug-drug interactions. The session will also offer a forum for interdisciplinary discussion on the utility of model-based drug development in the drug approval process. Additional information can be found at its Web site. "PK/PD modeling and simulation continue to gain currency as a valuable set of methods for improving the quality and value of drug development decisions," said Shawn O'Connor, President and CEO of Pharsight. "Exposure-response modeling and trial simulation are essential tools in today's global development environment, particularly where model-based insights can be leveraged to explore new treatment strategies and serve new patient populations. We are pleased to see growing interest in Pharsight's capabilities in the Japanese market, and Pharsight is pleased to participate in this distinguished gathering at the University of Tokyo to exchange information and best practices on the strategic application of modeling and simulation."